Results 221 to 230 of about 40,867 (262)
Some of the next articles are maybe not open access.
Current Osteoporosis Reports, 2019
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple ...
Olivier, Lamy +3 more
openaire +2 more sources
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple ...
Olivier, Lamy +3 more
openaire +2 more sources
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer [PDF]
New England Journal of Medicine, 2009 Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of ...
Fred Saad +2 more
exaly +3 more sources
Bone & Joint 360, 2013
It is not often that a new drug becomes available that is likely to affect the workload of orthopaedic surgeons, but denosumab has that potential. This edition of 360 carries a summary of a potentially landmark RCT examining the use of denosumab in giant cell tumour of bone. Denosumab is a fully human monoclonal antibody that inhibits RANK-L (Receptor
+5 more sources
It is not often that a new drug becomes available that is likely to affect the workload of orthopaedic surgeons, but denosumab has that potential. This edition of 360 carries a summary of a potentially landmark RCT examining the use of denosumab in giant cell tumour of bone. Denosumab is a fully human monoclonal antibody that inhibits RANK-L (Receptor
+5 more sources
Special Care in Dentistry: managing special patients, settings, and situations, 2023
OBJECTIVES This study aimed to assess the overall incidence of osteonecrosis of the jaw (ONJ) caused by bisphosphonates and denosumab when used for controlling bone cancer metastasis or as adjuvant therapy.
Chengrong Zhang +11 more
semanticscholar +1 more source
OBJECTIVES This study aimed to assess the overall incidence of osteonecrosis of the jaw (ONJ) caused by bisphosphonates and denosumab when used for controlling bone cancer metastasis or as adjuvant therapy.
Chengrong Zhang +11 more
semanticscholar +1 more source
Journal of Bone and Mineral Research
Denosumab is a highly effective treatment for osteoporosis, and its long-term use is associated with incremental gains in BMD and sustained fracture risk reduction.
Shejil Kumar +5 more
semanticscholar +1 more source
Denosumab is a highly effective treatment for osteoporosis, and its long-term use is associated with incremental gains in BMD and sustained fracture risk reduction.
Shejil Kumar +5 more
semanticscholar +1 more source
Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach
Aging Clinical and Experimental ResearchDenosumab produces a continuous increase in bone mineral density over ten years, associated with a low risk of vertebral and non-vertebral fractures. Denosumab is well tolerated and easy to manage in daily clinical practice.
Olivier Lamy +2 more
semanticscholar +1 more source
Current Opinion in Rheumatology, 2009
Denosumab is an investigational fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand, an essential mediator of osteoclastic bone resorption. Receptor activator of nuclear factor kappaB ligand plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheumatoid arthritis, and bone loss ...
openaire +2 more sources
Denosumab is an investigational fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand, an essential mediator of osteoclastic bone resorption. Receptor activator of nuclear factor kappaB ligand plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheumatoid arthritis, and bone loss ...
openaire +2 more sources
Journal of Bone and Mineral Research
Romosozumab following anti-resorptive can be an effective sequential treatment strategy to improve bone strength. However, whether the transition to romosozumab after denosumab is associated with greater improvement in bone mineral density (BMD) and ...
N. Hong +5 more
semanticscholar +1 more source
Romosozumab following anti-resorptive can be an effective sequential treatment strategy to improve bone strength. However, whether the transition to romosozumab after denosumab is associated with greater improvement in bone mineral density (BMD) and ...
N. Hong +5 more
semanticscholar +1 more source